Sandoz' 1994 Sales Advance 11%

23 January 1995

Particularly dynamic growth in the life sciences core sector, as a result of higher pharmaceutical sales and the Gerber acquisition, were the key driving forces behind the 11% sales growth achieved by Sandoz of Switzerland in 1994 expressed in local currency terms.

Group sales in 1994 were 15.9 billion Swiss francs ($12.4 billion), up 5% in Swiss francs.

Sales 1994 Sw Fr Local Mill Sw Fr Pharmaceuticals 7,196 -2% +4% Nutrition 2,771 +61% +67% Seeds 955 -3% +4% Life Sciences 10,922 +9% +15% Chemicals 2,324 -7% -1% Agro 1,368 +4% +9% Construction & 1,256 +2% +6% Environment Chemicals & 4,948 -2% +4% Environment Group Total 15,870 +5% +11%

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight